NCT03702114 is a clinical trial of auricular point detection in Menstrual Migraine, sponsored by The University of Hong Kong.

Who is sponsoring NCT03702114?

NCT03702114 is sponsored by The University of Hong Kong.

What drugs are being tested in NCT03702114?

Interventions in NCT03702114: auricular point detection.

What condition does NCT03702114 study?

NCT03702114 studies Menstrual Migraine.

Is NCT03702114 still recruiting?

NCT03702114 is currently status unknown. Last updated 10 October 2018.

Last reviewed 2018-10-10 · How we verify

NCT03702114

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Detecting Auricular Points in MMG by a Novel APD ( APD-MMG )

Status unknown Last updated 10 October 2018

What this trial tests

trial testing auricular point detection in Menstrual Migraine in 24 participants. Status unknown.

Timeline

15 October 2018

Primary endpoint
31 January 2019

31 March 2019

Quick facts

Lead sponsor	The University of Hong Kong
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	24
Start date	15 October 2018
Primary completion	31 January 2019
Estimated completion	31 March 2019
Sites	1 location across Hong Kong

Drugs / interventions tested

auricular point detection

Conditions studied

Menstrual Migraine — all drugs for Menstrual Migraine →

Sponsor

The University of Hong Kong

Who can join

Adults 18 to 40, female only, with Menstrual Migraine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot study is designed to validate the diagnostic ability of a novel APD for auricular point detection among patients with menstrual migraine (MMG), as compared with an already commercialized device.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Menstrual Migraine

Currently open trials in the same condition.

NCT06641466 — A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual · Phase 3 · recruiting
NCT06659120 — Fremanezumab for the Prevention of Menstrually-related Migraine Attacks · recruiting

Other The University of Hong Kong trials

Trials by the same sponsor.

NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03702114 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
Last refreshed: 10 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03702114.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing